Latest:
Dr. He Discusses Discovery of Cancer-Inducing Mutation in Thymic Epithelial Cells
Yongfeng He, PhD, discusses the identification of the GTF2I L424H mutation in mouse models of thymic cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jeanny B. Aragon-Ching, MD, FACP
Latest:
Considerations When Treating Patients With Metastatic Renal Cell Carcinoma
Similar to first-line therapy choices, particular treatment factors, including type
and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.
O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham
Latest:
Bredel Findings Address Understanding of Diffuse Gliomas
A groundbreaking discovery by Markus Bredel, MD, PhD, and colleagues not only marks a significant milestone in our understanding of diffuse gliomas but also paves the way for improved predictions of disease outcomes and the development of targeted treatment approaches.
Claire Roddie, MD, PhD
Latest:
Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study
Claire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Bogdana Schmidt
Bogdana Schmidt, MD, MPH, is an assistant professor in the Division of Urology at the University of Utah Huntsman Cancer Institute in Salt Lake City.
Latest:
Dr Schmidt on the Role of Minimally Invasive and Robotic Modalities in Bladder Cancer
Bogdana Schmidt, MD, MPH, discusses the role of minimally invasive and robotic strategies for the treatment of patients with bladder cancer.
Jessica C. Hassel, MD
Jessica C. Hassel, MD is a dermato-oncologist working at the University Hospital in Heidelberg, Germany.
Latest:
Dr Hassel on the Rationale for Combining IO102-IO103 with Pembrolizumab in Treatment-Naive Advanced Melanoma
Jessica C. Hassel, MD, discusses rationale for combining IO102-IO103 with pembrolizumab in patients with treatment-naive advanced melanoma.
Joachim G. J. V. Aerts, MD, PhD
Latest:
Dr Aerts on the Rationale for the DENIM Trial in Mesothelioma
Joachim G. J. V. Aerts, MD, PhD, discusses the rationale for conducting the phase 3 DENIM trial in patients with mesothelioma, highlighting the importance of focusing investigational efforts onto the dendritic cells.
UPMC Hillman Cancer Center
Latest:
Illumination of Immune Checkpoint LAG3 ‘Black Box’ Could Yield New Cancer and Autoimmune Therapies
A new study pinpoints how LAG3 modulates T cell activity, providing important insights for development of other LAG3-blocking therapies for cancer and autoimmune disorders.
Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania
Latest:
MET Inhibitors in NSCLC: Toxicity Management
Drs Joshua M. Bauml and Benjamin Levy highlight more common adverse events associated with MET inhibitors used to treat MET exon 14 skipping mutations in non–small cell lung cancer and share strategies to help manage patients on therapy.
Elizabeth A. Brem, MD
Elizabeth A. Brem, MD, is an associate clinical professor of medicine at the University of California Irvine.
Latest:
Dr Brem on the Potential Shift Away From Chemotherapy in Follicular Lymphoma
Elizabeth A. Brem, MD, highlights upcoming changes in the follicular lymphoma treatment paradigm that could move the field beyond chemotherapy.
Lydia Scarfò, MD
Lydia Scarfò, MD, is an assistant professor of internal medicine at the Università Vita-Salute San Raffaele; as well as a consultant hematologist at the Strategic Research Program on CLL
Latest:
Dr Scarfò on Early Safety Data With BGB-16673 in R/R CLL/SLL
Lydia Scarfò, MD, discusses early safety findings with the BTK degrader BGB-16673 in R/R CLL/SLL